BIND-014-005: An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel nanoparticles For Injectable Suspension) As Second-line Therapy To Patients With Non-Small Cell Lung Cancer
This study is for patients with stage III/IV non-small cell lung cancer (NSCLC) who have received one prior platinum-containing chemotherapy regimen for advanced or metastatic NSCLC. This study will assess the effectiveness of BIND-014 in patients who have stage III/IV NSCLC.
View the trial
This trial is offered at the following facilities:
Midwestern Regional Medical Center, Eastern Regional Medical Center, Southeastern Regional Medical Center, Southwestern Regional Medical Center, Western Regional Medical Center